Adaptive Biotechnologies Corporation (ADPT) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$16.44
Price Target
$21.25
Target Range
$21.00 — $22.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-15.2x
Forward PEG—
Implied Growth+0.7%
Median Target$21.00
Analyst Spread4.7%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$21
+27.7%
Consensus
$21
+29.3%
Bull Case
$22
+33.8%
ADPT Price Target Analysis
Updated March 5, 2026As of March 5, 2026, Adaptive Biotechnologies Corporation (ADPT) has a Wall Street consensus price target of $21.25, based on estimates from 17 covering analysts. With the stock currently trading at $16.44, this represents a potential upside of +29.3%. The company has a market capitalization of $2.51B.
Analyst price targets range from a low of $21.00 to a high of $22.00, representing a 5% spread in expectations. The median target of $21.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ADPT trades at a trailing P/E of -15.2x. Analysts expect EPS to grow +0.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+40.9%
Avg Forward P/E42.0x
Peers with Coverage5 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| ADPTAdaptive Biotechnologies Corporation | $2.5B | $16.44 | $21.25 | +29.3% | Buy | — | 17 |
 CAICaris Life Sciences, Inc. | $33.2B | $19.86 | $31.33 | +57.8% | Buy | 62.1x | 6 |
 VCYTVeracyte, Inc. | $2.9B | $36.27 | $47.25 | +30.3% | Buy | 22.0x | 20 |
 NAUTNautilus Biotechnology, Inc. | $331M | $2.62 | $2.50 | -4.6% | Buy | — | 5 |
 CDIOCardio Diagnostics Holdings, Inc. | $141M | $5.26 | — | — | — | — | — |
 SEERSeer, Inc. | $103M | $1.85 | — | — | Hold | — | 4 |
 IMDXInsight Molecular Diagnostics Inc. | $95M | $5.47 | $10.50 | +92.0% | Buy | — | 11 |
 ASBPAspire Biopharma Holdings, Inc. | $63M | $1.32 | — | — | — | — | — |
 YDESYD Bio Limited Ordinary Shares | $35M | $8.45 | — | — | — | — | — |
 AIMDAinos, Inc. | $7M | $1.51 | — | — | — | — | — |
Upside Potential Comparison
IMDXCAIVCYTADPTNAUTSee ADPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADPT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADPT vs LLY
See how ADPT stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
What is the ADPT stock price target for 2026?
The consensus Wall Street price target for ADPT is $21.25, representing 29.3% upside from the current price of $16.44. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is ADPT a buy, sell, or hold?
ADPT has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $21.25 implies 29.3% upside from current levels.
Is ADPT stock overvalued or undervalued?
ADPT's current price is $16.44 with a consensus target of $21.25 (29.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can ADPT stock go?
The most bullish Wall Street analyst has a price target of $22 for ADPT, while the most conservative target is $21. The consensus of $21.25 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ADPT stock?
ADPT is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 4 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ADPT stock forecast?
The 12-month ADPT stock forecast based on 17 Wall Street analysts shows a consensus price target of $21.25, with estimates ranging from $21 (bear case) to $22 (bull case). The median consensus rating is "Buy".
Should I buy ADPT stock?
Wall Street analysts are very optimistic on ADPT, with a "Buy" consensus rating and $21.25 price target (29.3% upside). 11 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ADPT price targets vary so much?
ADPT analyst price targets range from $21 to $22, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.25 consensus represents the middle ground.